ZeroStack Corp. Secures $6.5 Million Order from Major Pharmaceutical Company to Support Distribution in Germany

Rhea-AI Summary

ZeroStack (NASDAQ: ZSTK) secured a $6.5 million order for pharmaceutical distribution in Germany on March 4, 2026, to be fulfilled by its wholly owned German subsidiary Phatebo GmbH.

Phatebo, the company's largest revenue contributor, will leverage logistics, regulatory expertise, and potential AI tools to support timely, compliant distribution and recurrent cash flow for ZeroStack's broader AI-focused investment strategy.

Key Figures

Order value: $6.5 million Phatebo portfolio tenure: 5 years

2 metrics

Order value $6.5 million Pharmaceutical distribution order in Germany via Phatebo GmbH

Phatebo portfolio tenure 5 years Time Phatebo has served as a ZeroStack portfolio company

Market Reality Check

Price: $6.52 Vol: Volume 11,540 is well bel...

low vol

$6.52 Last Close

Volume Volume 11,540 is well below the 20-day average 34,546, indicating muted pre-news activity. low

Technical Price at $6.52 is trading below the 200-day MA of $8.85, reflecting a weak longer-term trend.

Peers on Argus

No peer stocks in the same sector appeared in the momentum scanner, suggesting t...

No peer stocks in the same sector appeared in the momentum scanner, suggesting this news is more company-specific than sector-driven.

Historical Context

1 past event · Latest: Feb 03 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	Crypto yield update	Positive	+8.3%	Reported first 1,000,000 0G tokens in staking rewards at ~21% APY.

Pattern Detected

The prior positive update on digital-asset rewards was followed by a positive price reaction, showing the stock has previously responded constructively to upbeat operational news.

Recent Company History

On Feb 3, 2026, ZeroStack reported earning its first 1,000,000 0G tokens in staking rewards, with a U.S. dollar equivalent of $840,000 at an estimated 21% APY. Shares moved 8.34% higher over the next 24 hours, aligning with the positive tone of that announcement. Today’s news shifts focus back to the core pharmaceutical distribution platform, highlighting a $6.5 million order in Germany through Phatebo GmbH, the company’s largest revenue contributor.

Market Pulse Summary

This announcement highlights a $6.5 million pharmaceutical distribution order in Germany, fulfilled ...

Analysis

This announcement highlights a $6.5 million pharmaceutical distribution order in Germany, fulfilled through Phatebo GmbH, ZeroStack’s largest revenue contributor. It underscores the company’s dual focus on a core European pharmaceutical platform and diversification into the artificial intelligence space. Historically, positive operational updates have coincided with constructive stock reactions. Investors may watch for follow-on contracts, progress on AI-enabled tools at Phatebo, and how these orders contribute to recurring cash flow and portfolio balance.

Key Terms

artificial intelligence

1 terms

artificial intelligence technical

"enabling ZeroStack to diversify its broader investment portfolio across the artificial intelligence ("AI") space."

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

AI-generated analysis. Not financial advice.

Order to be Fulfilled Through German Subsidiary Phatebo GmbH, Reinforcing Company's Core Pharmaceutical Distribution Platform

Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - ZeroStack Corp. (NASDAQ: ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured a $6.5 million order for the distribution in Germany. The order will be fulfilled through the Company's wholly owned German subsidiary, Phatebo GmbH ("Phatebo").

Phatebo is a pharmaceutical distributor in Europe and has served as a portfolio company of ZeroStack's operations for the past five years. In connection with the Company's integration plan, Phatebo is evaluating the use of AI-enabled tools to increase efficiency, reduce operational risk, and strengthen its ability to respond dynamically to market demand. As the Company's largest revenue contributor, Phatebo provides a reliable and recurring cash flow base while enabling ZeroStack to diversify its broader investment portfolio across the artificial intelligence ("AI") space.

Through Phatebo's established logistics network, regulatory expertise, and longstanding relationships across the European healthcare market, ZeroStack is well positioned to ensure timely and compliant distribution throughout Germany.

"This $6.5 million order underscores the strength of our pharmaceutical distribution platform and the trust global healthcare leaders place in Phatebo," said Daniel Reis-Faria, Chief Executive Officer of ZeroStack Corp. "Phatebo's consistent performance allows us not only to scale our pharmaceutical operations, but also to strategically diversify our investments, with the aim of creating long-term value for our stakeholders."

The order further solidifies the Company's position within the European pharmaceutical supply chain and highlights the Company's ability to execute high-value distribution agreements with globally recognized healthcare organizations.

As demand for innovative therapies continues to grow across Europe, ZeroStack intends to leverage Phatebo's infrastructure, compliance capabilities, and market relationships to expand its pharmaceutical distribution footprint.

About ZeroStack Corp.

ZeroStack Corp. is the first Nasdaq-listed asset management company focused on providing exposure to decentralized AI. The Company also operates a global pharmaceutical distribution business through its wholly owned subsidiary, Phatebo GmbH. For more information, visit https://zerostack.ai/.

Cautionary Statement Concerning Forward-Looking Statements

This press release may contain "forward-looking statements," as defined by U.S. federal securities laws. Forward-looking statements reflect the Company's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar words or expressions generally identify forward-looking statements. Such forward-looking statements are subject to various and risks and uncertainties, including those described under section entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on February 27, 2026,, as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov/edgar. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based on information currently available to the Company (or to third parties making the forward-looking statements).

Investor Contact: ir@zerostack.ai

Media Contact: zerostack@dittopr.co

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286229

FAQ

What is the $6.5 million order announced by ZeroStack (ZSTK) on March 4, 2026?

It is a $6.5 million pharmaceutical distribution order for Germany fulfilled via Phatebo GmbH. According to the company, Phatebo will use its logistics and regulatory capabilities to deliver products and support compliant distribution across German healthcare channels.

How will the March 4, 2026 ZSTK order affect Phatebo's operations in Germany?

The order increases near-term distribution activity and revenue for Phatebo in Germany. According to the company, Phatebo will deploy its established logistics network and compliance processes to meet demand and ensure timely delivery to healthcare customers.

Does the ZSTK announcement say Phatebo will use AI tools to support distribution?

Yes, Phatebo is evaluating AI-enabled tools to boost efficiency and reduce operational risk. According to the company, these tools aim to improve responsiveness to market demand and strengthen Phatebo's operational resilience across Europe.

Is Phatebo described as a significant contributor to ZeroStack's revenue (ZSTK)?

Yes, Phatebo is described as the company's largest revenue contributor and a source of recurring cash flow. According to the company, Phatebo's performance underpins ZeroStack's ability to diversify investments across the AI space.

What does the March 4, 2026 ZSTK order signal about ZeroStack's European strategy?

The order underscores ZeroStack's push into European pharmaceutical distribution and supply-chain presence. According to the company, leveraging Phatebo's infrastructure and relationships positions ZeroStack to expand its distribution footprint in Germany and broader Europe.